Drug Profile
Epcoritamab - Genmab/AbbVie
Alternative Names: ABBV-GMAB-3013; Anti-CD3 anti-CD20 bispecific antibody - Genmab/AbbVie; Duobody-CD3-CD20; DuoBody-CD3xCD20; Epcoritamab-bysp; EPKINLY; GEN-3013; Tepkinly; TEPKINLYLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Genmab
- Developer AbbVie; Genmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diffuse large B cell lymphoma
- Preregistration Follicular lymphoma
- Phase II Non-Hodgkin's lymphoma
- Phase I/II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Richter's syndrome